ClinicalTrials.gg
CompletedNCT03037203Updated Jan 9, 2020Results posted

A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness

A Phase 2 interventional study of JZP-110 and Placebo in Excessive Sleepiness and Parkinson Disease, sponsored by Jazz Pharmaceuticals. Completed at 25 sites in United States. Open to participants aged 35 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-01-09.

Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
35 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing solriamfetol in Disorders of Excessive Somnolence — 3 open to participants now, 3 under way, 2 of them phase 3. solriamfetol · Disorders of Excessive Somnolence.

Enrollment
7th of 12
66 · median 75
Started
2017
the only one that year
Phase 2
6 of 12
1 open now
Registered
3rd of 12
by date
Lead sponsor
3 of 12
Jazz Pharmaceuticals

Among the 12 studies testing solriamfetol in Disorders of Excessive Somnolence, this one is the 7th largest by enrollment, is the only one that started in 2017, is one of 6 in phase 2, and was the 3rd registered.

Disorders of Excessive Somnolence

196 studies on the registry are indexed under Disorders of Excessive Somnolence; 34 are open to participants now.

Browse Disorders of Excessive Somnolence studies →

Open to participants now

3 of the 12 studies testing solriamfetol in Disorders of Excessive Somnolence are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About solriamfetol

solriamfetol: first FDA approval 2019 (SUNOSI), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Disorders of Excessive Somnolence studies recruiting now, 12 (40%) set no upper age limit and 17 (57%) stop at 75 or younger; 5 take children under 18; 7 take healthy volunteers.

This study: 35 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing solriamfetol in Disorders of Excessive Somnolence, or all of them as a file.
02

Study summary

This study is a 4-week, multicenter, randomized, double-blind, placebo-controlled, ascending dose, 4-period crossover study designed to evaluate the safety, tolerability, efficacy, and PK of JZP-110 (75, 150, and 300 mg) in the treatment of excessive sleepiness in adult subjects with idiopathic PD.

03

Conditions studied

  • Excessive Sleepiness
  • Parkinson Disease
04

Who can participate

Ages eligible
35 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of idiopathic PD according to the UK PDS Brain Bank Criteria.
  2. Hoehn and Yahr stage 1, 2, or 3.
  3. Screening and Baseline ESS scores >11.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of other degenerative Parkinsonian syndromes (e.g., progressive supranuclear palsy, multiple system atrophy [MSA], or dementia with Lewy bodies [DLB]).
  2. Usual nightly time in bed of \<6 hours, including the night before the Baseline visit.
  3. Untreated or inadequately treated moderate to severe OSA.
  4. Has evidence at screening of severe cognitive impairment or has cognitive impairment that in the opinion of the investigator would prevent completion of study procedures or the ability to provide .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Arm A

    JZP-110 and Placebo

    Drug: JZP-110 · Other: Placebo

  • Experimental
    Arm B

    JZP-110 and Placebo

    Drug: JZP-110 · Other: Placebo

  • Placebo comparator
    Arm C

    Placebo

    Other: Placebo

Interventions

  • 75 mg, 150 mg, 300 mg

  • OtherPlacebo
06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Early Discontinuation

    Time frame: Up to Day 35

Secondary outcomes

  1. Change From Baseline in Epworth Sleepiness Scale (ESS) Total Score

    Change from Baseline ESS defined in terms of change from study baseline (prior to first dose in Period 1) to the end of each Treatment Period (Weeks 1, 2, 3, and 4). The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions, asking subjects how likely they would be to doze off or fall asleep in different situations. Responses range from 0 = would never doze to 3 = high chance of dozing. Higher scores represent greater severity of excessive sleepiness. The total score ranges from 0 - 24, with higher scores representing greater severity of excessive sleepiness.

    Time frame: Baseline to Weeks 1, 2, 3, and 4

Other outcomes

  1. Change From Baseline in the Mean Sleep Latency Time (in Minutes) on the Maintenance of Wakefulness Test (MWT)

    Change from Baseline mean sleep latency (in minutes) on the MWT defined in terms of change from study baseline (prior to first dose in Period 1) to the end of each Treatment Period (Weeks 1, 2, 3, and 4). The MWT is the standard objective measure of an individual's ability to remain awake during the daytime in a darkened, quiet environment. MWT sleep latency ranges from 0 to 40 minutes, with higher scores indicated greater ability to stay awake.

    Time frame: Baseline to Weeks 1, 2, 3, and 4

07

Results

Posted Jan 9, 2020

Participant flow

Participant flow — Overall Study
MilestoneTreatment Sequence ATreatment Sequence BTreatment Sequence C
Started282810
Completed27269
Not completed121

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Early Discontinuation
Time frame:
Up to Day 35
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Early Discontinuation
ParticipantsJZP-110 75mgJZP-110 150mgJZP-110 300mgPlacebo
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Early Discontinuation1200
SecondaryChange From Baseline in Epworth Sleepiness Scale (ESS) Total Score

Change from Baseline ESS defined in terms of change from study baseline (prior to first dose in Period 1) to the end of each Treatment Period (Weeks 1, 2, 3, and 4). The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions, asking subjects how likely they would be to doze off or fall asleep in different situations. Responses range from 0 = would never doze to 3 = high chance of dozing. Higher scores represent greater severity of excessive sleepiness. The total score ranges from 0 - 24, with higher scores representing greater severity of excessive sleepiness.

Time frame:
Baseline to Weeks 1, 2, 3, and 4
Reported as:
Least squares mean · score on a scale
Change From Baseline in Epworth Sleepiness Scale (ESS) Total Score
score on a scaleJZP-110 75mgJZP-110 150mgJZP-110 300mgPlacebo
Change From Baseline in Epworth Sleepiness Scale (ESS) Total Score-4.82 ± 0.67-5.04 ± 0.70-5.72 ± 0.68-4.78 ± 0.58
Other pre-specifiedChange From Baseline in the Mean Sleep Latency Time (in Minutes) on the Maintenance of Wakefulness Test (MWT)

Change from Baseline mean sleep latency (in minutes) on the MWT defined in terms of change from study baseline (prior to first dose in Period 1) to the end of each Treatment Period (Weeks 1, 2, 3, and 4). The MWT is the standard objective measure of an individual's ability to remain awake during the daytime in a darkened, quiet environment. MWT sleep latency ranges from 0 to 40 minutes, with higher scores indicated greater ability to stay awake.

Time frame:
Baseline to Weeks 1, 2, 3, and 4
Reported as:
Least squares mean · minutes
Change From Baseline in the Mean Sleep Latency Time (in Minutes) on the Maintenance of Wakefulness Test (MWT)
minutesJZP-110 75mgJZP-110 150mgJZP-110 300mgPlacebo
Change From Baseline in the Mean Sleep Latency Time (in Minutes) on the Maintenance of Wakefulness Test (MWT)0.4289 ± 2.12542.6721 ± 2.19616.8133 ± 2.13511.7670 ± 1.8479

Adverse events

Collected over Up to Day 35. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
JZP-110 75 mg0/56 (0%)0/56 (0%)4/56 (7.1%)
JZP-110 150 mg0/55 (0%)0/55 (0%)5/55 (9.1%)
JZP-110 300 mg0/54 (0%)1/54 (1.9%)4/54 (7.4%)
Placebo0/64 (0%)0/64 (0%)0/64 (0%)
Most frequent serious events
Most frequent serious events
EventJZP-110 75 mgJZP-110 150 mgJZP-110 300 mgPlacebo
HaematuriaRenal and urinary disorders0/560/551/540/64
Most frequent other events
Most frequent other events
EventJZP-110 75 mgJZP-110 150 mgJZP-110 300 mgPlacebo
NauseaGastrointestinal disorders2/562/553/540/64
HeadacheNervous system disorders1/563/552/540/64
DizzinessNervous system disorders3/560/551/540/64

Baseline characteristics

Age, Continuous
Age, Continuous(years)Treatment Sequence ATreatment Sequence BTreatment Sequence CTotal
Mean65.9 ± 7.6462.9 ± 8.7565.4 ± 9.7564.6 ± 8.45
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Sequence ATreatment Sequence BTreatment Sequence CTotal
Female106521
Male1822545
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment Sequence ATreatment Sequence BTreatment Sequence CTotal
American Indian or Alaska Native0101
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American1214
White2724960
More than one race0000
Unknown or Not Reported0101
08

Study locations

25 sites
  • Southern California Institute For Respiratory Diseases, Inc.
    Los Angeles, California 90048, United States
  • Pacific Research Network, Inc
    San Diego, California 92103, United States
  • Alpine Clinical Research Center
    Boulder, Colorado 80301, United States
  • Rocky Mountain Movement Disorders Center, PC
    Englewood, Colorado 80113, United States
  • Parkinson's Disease and Movement Disorders Center of Boca Raton
    Boca Raton, Florida 33486, United States
  • PAB Clinical Research
    Brandon, Florida 33511, United States
  • MD Clinical
    Hallandale Beach, Florida 33009, United States
  • QPS MRA (Miami Research Associates)
    Miami, Florida 33143, United States
  • Bioclinica Research
    Orlando, Florida 32806, United States
  • USF Health Byrd Institute
    Tampa, Florida 33613, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Kansas Medical Center Research Institute, Inc.
    Kansas City, Kansas 66160, United States
  • Center for Sleep & Wake Disorders
    Chevy Chase, Maryland 20815, United States
  • QUEST Research Institute
    Farmington Hills, Michigan 48334, United States
  • Clinical Neurophysiology Services, P.C.
    Sterling Heights, Michigan 48314, United States
  • Henry Ford Medical Center - West Bloomfield
    West Bloomfield, Michigan 48322, United States
  • St. Lukes Hospital Medical Center
    Chesterfield, Missouri 63017, United States
  • Montefiore Sleep-Wake Disorders Center
    Bronx, New York 10467, United States
  • Strong Sleep Disorders Center
    Rochester, New York 14618, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Parkinson's Disease Research Unit - Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • SleepMed of South Carolina
    Columbia, South Carolina 29201, United States
  • Villages at Vanderbilt
    Nashville, Tennessee 37232, United States
  • Evergreen Hospital Medical Center
    Kirkland, Washington 98034, United States
  • Premier Clinical Research - Sherman
    Spokane, Washington 99202, United States
09

References and documents

Publications

  • Videnovic A, Amara AW, Comella C, Schweitzer PK, Emsellem H, Liu K, Sterkel AL, Gottwald MD, Steinerman JR, Jochelson P, Zomorodi K, Hauser RA. Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial. Mov Disord. 2021 Oct;36(10):2408-2412. doi: 10.1002/mds.28702. Epub 2021 Jun 30. PubMed 34191352 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2017, a primary completion of Aug 2018 and a completion of Aug 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2020, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2017
First posted
Jan 31, 2017
Start
Jan 2017
Primary completionActual
Aug 2018
CompletionActual
Aug 2018
Results first posted
Jan 9, 2020
Last update
Jan 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03037203
Responsible party
Sponsor
First posted
Jan 31, 2017
Start date
Jan 2017
Primary completion
Aug 2018
Completion
Aug 2018
Results posted
Jan 9, 2020
Last update
Jan 9, 2020

Study contacts

Millie Gottwald, PharmD
study director · Jazz Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solriamfetol

Start the discussion